MannKind Corp (MNKD) shareholders
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 22,297,032 | 8.30% | 13G (passive) amendment | Dec 31, 2023 |
| Rubric Capital Management LP Joint filing with David Rosen (5.83%) | 18,000,000 | 5.83% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 15,450,421 | 5.00% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MNKD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 32,133,223 | 9.99% | $136.89M | +3,532,225 | 0.00% |
| Rubric Capital Management LP | 18,000,000 | 5.60% | $76.68M | +14,379,587 | 0.70% |
| State Street Corp | 16,174,043 | 5.03% | $68.90M | −2,509,440 | 0.00% |
| Vanguard Capital Management LLC | 13,169,392 | 4.10% | $56.10M | +278,326 | 0.00% |
| Geode Capital Management, LLC | 7,947,203 | 2.47% | $33.86M | +442,056 | 0.00% |
| Wellington Management Group Llp | 7,844,807 | 2.44% | $33.42M | +4,561,628 | 0.01% |
| Frazier Life Sciences Management, L.P. | 6,600,000 | 2.05% | $28.12M | +700,000 | 0.61% |
| Deep Track Capital, LP | 6,000,000 | 1.87% | $25.56M | New | 0.37% |
| 180 Wealth Advisors, LLC | 4,959,351 | 1.54% | $21.13M | +667,648 | 2.12% |
| FMR LLC | 4,101,046 | 1.28% | $17.47M | +620,082 | 0.00% |
| TSP Capital Management Group, LLC | 3,972,675 | 1.24% | $16.92M | New | 4.05% |
| Aqr Capital Management LLC | 3,808,824 | 1.18% | $16.23M | +3,355,838 | 0.01% |
| Morgan Stanley | 3,474,870 | 1.08% | $14.80M | −2,318,277 | 0.00% |
| Braidwell LP | 3,458,429 | 1.08% | $14.73M | New | 0.54% |
| Vanguard Portfolio Management LLC | 3,002,169 | 0.93% | $12.79M | −169,655 | 0.00% |
| Northern Trust Corp | 2,887,290 | 0.90% | $12.30M | +211,340 | 0.00% |
| UBS Group AG | 2,886,231 | 0.90% | $12.30M | −5,369,199 | 0.00% |
| Two Sigma Investments, LP | 2,693,712 | 0.84% | $11.48M | −202,162 | 0.01% |
| Charles Schwab Investment Management Inc | 2,598,727 | 0.81% | $11.07M | +49,660 | 0.00% |
| Bank Of America Corp /De/ | 2,364,872 | 0.74% | $10.07M | −1,018,805 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 259 | 182M | 56.7% | 52 / 96 | 62 / 39 | 51M | 46M |
| Q1 2026 | 250 | 177M | 55.0% | 45 / 84 | 71 / 50 | 52M | 35M |
| Q4 2025 | 258 | 178M | 55.4% | 48 / 86 | 69 / 22 | 26M | 23M |
| Q3 2025 | 234 | 175M | 54.4% | 51 / 60 | 75 / 46 | 37M | 30M |
| Q2 2025 | 232 | 168M | 52.3% | 24 / 74 | 71 / 48 | 19M | 27M |
| Q1 2025 | 257 | 177M | 55.1% | 43 / 81 | 71 / 27 | 24M | 13M |
| Q4 2024 | 244 | 168M | 52.3% | 43 / 93 | 50 / 26 | 23M | 8M |
| Q3 2024 | 231 | 155M | 48.1% | 39 / 81 | 52 / 17 | 47M | 8M |
| Q2 2024 | 211 | 138M | 43.0% | 33 / 67 | 62 / 23 | 15M | 17M |
| Q1 2024 | 204 | 140M | 43.5% | 41 / 54 | 55 / 37 | 21M | 16M |
| Q4 2023 | 201 | 135M | 42.0% | 27 / 63 | 49 / 22 | 12M | 15M |
| Q3 2023 | 196 | 139M | 43.2% | 25 / 63 | 53 / 14 | 17M | 12M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
157 funds held MNKD in Q2 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MNKD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 9,327,332 | 2.90% | $39.73M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 8,517,947 | 2.65% | $36.29M | 0.34% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 7,992,093 | 2.49% | $34.05M | 0.04% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 4,078,401 | 1.27% | $15.38M | 0.29% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 3,526,693 | 1.10% | $15.02M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 3,361,980 | 1.05% | $13.15M | 0.04% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,841,882 | 0.88% | $12.11M | 0.08% | Jun 30, 2026 |
| iShares Biotechnology ETF | 2,077,728 | 0.65% | $8.85M | 0.10% | Jun 30, 2026 |
| Janus Henderson Small/Mid Cap Growth Alpha ETF | 1,678,187 | 0.52% | $6.56M | 0.62% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 1,592,082 | 0.50% | $6.00M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 1,570,158 | 0.49% | $5.92M | 0.03% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,466,402 | 0.46% | $5.53M | 0.02% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 1,334,950 | 0.42% | $5.03M | 0.10% | May 29, 2026 |
| First Trust Small Cap Growth AlphaDEX Fund | 1,212,660 | 0.38% | $4.74M | 0.37% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 869,782 | 0.27% | $3.28M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Castagna | Chief Executive Officer, Director | 2,494,183 | 0.78% | Jul 17, 2026 |
| David Thomson | EVP Genl Counsel & Secretary | 797,554 | 0.25% | Jul 17, 2026 |
| Christopher B. Prentiss | Chief Financial Officer | 318,668 | 0.10% | Jul 17, 2026 |
| Sanjay R. Singh | EVP Technical Operations | 478,966 | 0.15% | Jul 17, 2026 |
| Stuart A. Tross | Chief People & Workpl Officer | 1,123,950 | 0.35% | Jul 17, 2026 |
| Dominic Marasco | Pres, Endocrine Business Unit | 343,398 | 0.11% | Jul 17, 2026 |
| Ajay Ahuja | Chief Medical Officer | 318,200 | 0.10% | Mar 25, 2026 |
| Burkhard Blank | EVP Chief Medical Officer | 460,791 | 0.14% | Jul 17, 2025 |
| Lauren M. Sabella | EVP Operations | 349,841 | 0.11% | Jul 17, 2025 |
| Steven B. Binder | Director | 713,258 | 0.22% | Sep 28, 2026 |
| James Samuel Shannon | Director | 36,458 | 0.01% | May 22, 2026 |
| Christine Mundkur | Director | 27,675 | 0.01% | May 22, 2026 |
| Jennifer Grancio | Director | 110,701 | 0.03% | May 22, 2026 |
| Sabrina Kay | Director | 107,033 | 0.03% | May 22, 2026 |
| Michael A. Friedman | Director | 86,700 | 0.03% | May 22, 2026 |
| Ronald J. Consiglio | Director | 132,342 | 0.04% | May 22, 2026 |
| Anthony C. Hooper | Director | 236,153 | 0.07% | May 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Steven B. Binder Director | Sep 25, 2026 | Sale(10b5-1 plan) | −39,051 | $3.29 | $128.48K | 713,258 |
| Steven B. Binder Director | Sep 10, 2026 | Sale(10b5-1 plan) | −33,558 | $3.81 | $127.86K | 752,309 |
| Steven B. Binder Director | Aug 7, 2026 | Sale(10b5-1 plan) | −39,051 | $4.06 | $158.55K | 785,867 |
| David Thomson EVP Genl Counsel & Secretary | Jul 17, 2026 | Sale(10b5-1 plan) | −24,109 | $4.05 | $97.64K | 797,554 |
| Steven B. Binder Director | Jul 17, 2026 | Sale(10b5-1 plan) | −52,485 | $4.06 | $213.09K | 824,918 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Option exercise | +93,790 | – | – | 1,123,950 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Tax withholding | −33,652 | $4.09 | $137.64K | 1,090,298 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Tax withholding | −8,253 | $4.09 | $33.75K | 1,082,045 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Tax withholding | −11,572 | $4.09 | $47.33K | 1,070,473 |
| Stuart A. Tross Chief People & Workpl Officer | Jul 15, 2026 | Tax withholding | −12,331 | $4.09 | $50.43K | 1,058,142 |
| Dominic Marasco Pres, Endocrine Business Unit | Jul 15, 2026 | Tax withholding | −3,623 | $4.09 | $14.82K | 343,398 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Tax withholding | −63,996 | $4.09 | $261.74K | 2,492,683 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Tax withholding | −58,904 | $4.09 | $240.92K | 2,433,779 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Tax withholding | −47,481 | $4.09 | $194.20K | 2,556,679 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Option exercise | +350,260 | – | – | 2,796,979 |
| Michael Castagna Chief Executive Officer, Director | Jul 15, 2026 | Tax withholding | −192,819 | $4.09 | $788.63K | 2,604,160 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Tax withholding | −9,297 | $4.09 | $38.02K | 478,966 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Tax withholding | −10,079 | $4.09 | $41.22K | 488,263 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Tax withholding | −5,372 | $4.09 | $21.97K | 498,342 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Option exercise | +70,550 | – | – | 525,761 |
| Sanjay R. Singh EVP Technical Operations | Jul 15, 2026 | Tax withholding | −22,047 | $4.09 | $90.17K | 503,714 |
| Christopher B. Prentiss Chief Financial Officer | Jul 15, 2026 | Tax withholding | −10,675 | $4.09 | $43.66K | 318,668 |
| Christopher B. Prentiss Chief Financial Officer | Jul 15, 2026 | Tax withholding | −11,572 | $4.09 | $47.33K | 329,343 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Option exercise | +93,790 | – | – | 920,089 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Tax withholding | −51,632 | $4.09 | $211.17K | 868,457 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Tax withholding | −12,662 | $4.09 | $51.79K | 855,795 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Tax withholding | −17,754 | $4.09 | $72.61K | 838,041 |
| David Thomson EVP Genl Counsel & Secretary | Jul 15, 2026 | Tax withholding | −16,378 | $4.09 | $66.99K | 821,663 |
| Steven B. Binder Director | Jul 15, 2026 | Tax withholding | −4,073 | $4.09 | $16.66K | 882,037 |
| Steven B. Binder Director | Jul 15, 2026 | Tax withholding | −4,634 | $4.09 | $18.95K | 877,403 |
| Steven B. Binder Director | Jul 15, 2026 | Tax withholding | −15,688 | $4.09 | $64.16K | 886,110 |
| Steven B. Binder Director | Jul 15, 2026 | Option exercise | +93,790 | – | – | 901,798 |
| Stuart A. Tross Chief People & Workpl Officer | May 20, 2026 | Award | +33,898 | $2.95 | $100.00K | 1,026,122 |
| Ronald J. Consiglio Director | May 20, 2026 | Award | +10,000 | $2.95 | $29.50K | 132,342 |
| Dominic Marasco Pres, Endocrine Business Unit | May 20, 2026 | Award | +8,474 | $2.95 | $25.00K | 344,246 |
| Steven B. Binder Director | May 12, 2026 | Sale(10b5-1 plan) | −16,940 | $3.29 | $55.73K | 808,008 |
| David Thomson EVP Genl Counsel & Secretary | May 12, 2026 | Sale(10b5-1 plan) | −3,033 | $3.29 | $9.98K | 826,299 |
| Steven B. Binder Director | May 11, 2026 | Tax withholding | −5,560 | $3.52 | $19.57K | 824,948 |
| David Thomson EVP Genl Counsel & Secretary | May 11, 2026 | Tax withholding | −12,387 | $3.52 | $43.60K | 829,332 |
| Michael Castagna Chief Executive Officer, Director | May 11, 2026 | Tax withholding | −34,957 | $3.52 | $123.05K | 2,442,310 |
| Stuart A. Tross Chief People & Workpl Officer | May 11, 2026 | Tax withholding | −8,073 | $3.52 | $28.42K | 992,224 |
| Christopher B. Prentiss Chief Financial Officer | Apr 22, 2026 | Tax withholding | −12,267 | $2.74 | $33.61K | 338,924 |
| Michael Castagna Chief Executive Officer, Director | Mar 10, 2026 | Buy | +100,000 | $2.59 | $259.00K | 2,575,911 |
| James Samuel Shannon Director | Mar 1, 2026 | Award | +12,000 | $3.27 | $39.24K | 64,635 |
| Christopher B. Prentiss Chief Financial Officer | Mar 1, 2026 | Award | +5,000 | $3.27 | $16.35K | 348,854 |
| Anthony C. Hooper Director | Mar 1, 2026 | Award | +35,000 | $3.27 | $114.45K | 236,153 |
| Michael Castagna Chief Executive Officer, Director | Mar 1, 2026 | Award | +15,290 | $3.27 | $50.00K | 2,475,911 |
| Stuart A. Tross Chief People & Workpl Officer | Mar 1, 2026 | Award | +15,290 | $3.27 | $50.00K | 1,000,297 |
| Stuart A. Tross Chief People & Workpl Officer | Jan 8, 2026 | Sale(10b5-1 plan) | −47,006 | $6.33 | $297.55K | 985,007 |
| Michael Castagna Chief Executive Officer, Director | Dec 24, 2025 | Gift | −44,171 | – | – | 2,460,621 |
| Michael Castagna Chief Executive Officer, Director | Dec 17, 2025 | Option exercise | +65,804 | $4.55 | $299.41K | 2,570,596 |
| Michael Castagna Chief Executive Officer, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −65,804 | $6.01 | $395.48K | 2,504,792 |
| Michael Castagna Chief Executive Officer, Director | Dec 16, 2025 | Sale(10b5-1 plan) | −21,310 | $6.00 | $127.86K | 2,504,792 |
| Michael Castagna Chief Executive Officer, Director | Dec 16, 2025 | Option exercise | +21,310 | $4.55 | $96.96K | 2,526,102 |
| Michael Castagna Chief Executive Officer, Director | Dec 12, 2025 | Option exercise | +20,806 | $4.55 | $94.67K | 2,525,598 |
| Michael Castagna Chief Executive Officer, Director | Dec 12, 2025 | Sale(10b5-1 plan) | −20,806 | $6.00 | $124.84K | 2,504,792 |
| Michael Castagna Chief Executive Officer, Director | Dec 2, 2025 | Sale(10b5-1 plan) | −107,920 | $5.57 | $601.11K | 2,504,792 |
| Michael Castagna Chief Executive Officer, Director | Dec 2, 2025 | Option exercise | +107,920 | $4.55 | $491.04K | 2,612,712 |
| David Thomson EVP Genl Counsel & Secretary | Dec 2, 2025 | Option exercise | +60,000 | $4.55 | $273.00K | 901,719 |
| David Thomson EVP Genl Counsel & Secretary | Dec 2, 2025 | Option exercise | +87,780 | $4.60 | $403.79K | 989,499 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MannKind's stock actually held short. Settlement fails (shares not delivered on time) peaked at 18,086 shares on Sep 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Steven B. Binder Director | Sep 25, 2026 | 39,051 | $128.48K | Sep 25, 2026 | Performance Stock Units |
| Steven B. Binder Director | Sep 10, 2026 | 33,558 | $132.22K | Sep 10, 2026 | Restricted Stock Units |
| Steven B. Binder Director | Aug 7, 2026 | 39,051 | $151.91K | Aug 7, 2026 | Performance Stock Units |
| Steven B. Binder Director | Jul 17, 2026 | 52,485 | $212.04K | Jul 17, 2026 | Restricted Stock Units |
| David Thomson Officer | Jul 17, 2026 | 24,109 | $97.40K | Jul 17, 2026 | Restricted Stock Units |
| David Thomson Officer | May 14, 2026 | 3,033 | $9.89K | May 12, 2026 | Restricted Stock Units |
| Steven B. Binder Director | May 12, 2026 | 16,940 | $56.92K | May 12, 2026 | Restricted Stock Units |
| David Thomson Officer | May 12, 2026 | 10,113 | $33.98K | May 12, 2026 | Restricted Stock Units |
| Stuart A. Tross Officer | Jan 8, 2026 | 47,000 | $297.51K | Jan 8, 2026 | Performance Shares |
| Michael Castagna Director, Officer | Dec 12, 2025 | 107,920 | $627.02K | Dec 12, 2025 | Exercise of Stock Options |
| David Thomson Officer | Dec 2, 2025 | 147,780 | $802.45K | Dec 2, 2025 | Exercise of Stock Options |
| Michael Castagna Director, Officer | Dec 2, 2025 | 107,920 | $586.01K | Dec 2, 2025 | Exercise of Stock Options |
| Sanjay R. Singh Officer | Nov 14, 2025 | 18,777 | $94.49K | Nov 14, 2025 | Restricted Stock |
| Stuart A. Tross Officer | Sep 16, 2025 | 47,000 | $250.79K | Sep 16, 2025 | Performance Shares |
| David Thomson Officer | Jul 16, 2025 | 7,466 | $29.43K | Jul 16, 2025 | Restricted Stock |
See a number that looks wrong?